Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Two Rabbit Monoclonal Antibodies Released for Cancer Diagnosis

By LabMedica International staff writers
Posted on 14 May 2014
A provider of cancer diagnostic solutions announced the addition of two new antibodies, Anti-CK 8/18 and Anti-TdT, to a portfolio of high-quality reagents, instruments, and software.

Anti-CK 8/18 is the first rabbit monoclonal antibody cocktail for cytokeratin 8/18 (CK 8/18) available from a major pathology provider. More...
It is used by pathologists to stain CK 8/18 in tissue samples and thereby help classify tumors of unknown origin. Keratins are one of the most potent epithelial differentiation and tumor markers in cancer diagnostics.

Anti-TdT, also a rabbit monoclonal antibody, is used to help classify lymphoma and leukemia by staining terminal deoxynucleotidyl transferase (TdT) in tissue samples. In immunohistochemistry, antibodies to TdT can be used to demonstrate the presence of pre-T and pre-B cells and multipotent hematopoietic stem cells that possess the antigen.

Both antibodies are available from Dako now as 1.0 mL concentrates and 12 mL (60 tests).

Dako (Glostrup, Denmark) released the antibodies Anti-CK 8/18 and Anti-TdT, which provide good specificity and sensitivity, and have been evaluated and accepted by pathologists. Both antibodies provide optimal staining results with the FLEX ready-to-use Dako solutions. FLEX ready-to-use is a plug-and-play solution consisting of pre-diluted antibodies, a visualization system, and optimized validated protocols developed in collaboration with pathologists. The protocols are developed to take into account pre-analytical variations and different ways of processing and handling tissue samples, ensuring optimal staining results for pathology labs.

Hans Christian Pedersen, global product manager, Dako said, "With the FLEX RTU solution, it takes less time for a lab to validate new antibodies for routine diagnostic use. FLEX ready-to-use antibodies are helping labs get high-quality results from day one."

"We are pleased to add these two high-quality antibodies to our comprehensive offering to pathologists around the world," said Britt Meelby Jensen, vice president of marketing and pathology sales in Agilent's diagnostics and genomics business. "One of our goals is to constantly establish new quality benchmarks within IHC reagents."

Agilent Technologies Inc. (Santa Clara, CA, USA) is a measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics, and communications. In 2012, it acquired Dako a provider of reagents, instruments, software, and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients.

Related Links:

Dako

Agilent



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.